Updated official USP Chapters 797 & 800
Revisions to USP Chapters <797> & <795> were published in November 2022 and will become official in November 2023. Many pharmacists and technicians have a high-level understanding of these revisions; however, many are unfamiliar with all of the details and required changes needed for compliance. Participants will learn key topics in each section and how these important guidelines affect operations, safety and patient care.
Target Audience
This activity is intended for pharmacists and pharmacy technicians.
Learning Objectives
Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to:
- Discuss changes to recently revised USP Chapters <797> and <800>.
- Identify necessary operational processes needed to meet compliance.
- Develop required Standard Operating Procedures as outlined in the chapters.
Pharmacy technician learning objectives
At the conclusion of this activity, pharmacy technicians should be able to:
- Develop strategies for following proper methods when preparing compounded sterile and non-sterile preparations.
- Describe various methods utilized to minimize the exposure of hazardous drugs.
Faculty
Carolyn Liptak, MBA, BS Pharm
Pharmacy Executive Director
Vizient, Inc.
Planning committee
Madalene Klocke, BA
Project Manager
Vizient, Inc.
Mallory Fiorenza, PharmD, BCPS, BCCCP
Pharmacy Executive Director
Vizient, Inc.
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of content validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Joint Accreditation Statement:
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statement(s):
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.0 ACPE credit hours.
Universal Activity Number: JA0006103-0000-23-329-L07-P
Universal Activity Number: JA0006103-0000-23-329-L07-T
OTHER
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re- certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE - Attendance